

Arden and Greater East Midlands Commissioning Support Unit in association with
Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust

Lincolnshire *PACE* Shorts

Summary of PACEF decisions from April 2015

For further details see *PACE Bulletin* Volume 9 No 8 (May 2015)

Drug	Indication(s)	Traffic Light and <i>Joint Formulary</i> Status
<i>Anthelios SPF 50+ Melt In Cream</i> (La Roche-Posay)	For protection from UV radiation in abnormal cutaneous photosensitivity resulting from genetic disorders or photo-dermatoses, including vitiligo and those resulting from radiotherapy. For chronic or recurrent herpes simplex labialis.	GREEN. Subject to ACBS restricted indications (Drug Tariff Part XV Borderline Substances). Included in the <i>Lincolnshire Joint Formulary</i> for these restricted indications. Sunscreens should not be prescribed for any other indication.
Brimonidine tartrate 3mg/g gel (<i>Mirvaso</i>) (Galderma)	Symptomatic treatment of facial erythema due to rosacea	AMBER without shared care. Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> . Restricted to patients with moderate to severe persistent erythema of rosacea that is causing significant psychological or social distress.
<i>Calcichew D3 1g/800iu Once Daily</i> chewable tablets (calcium 1g/ Vit D 800i.u.) (Takeda)	For the prevention and treatment of vitamin D and calcium deficiency in the elderly and as an adjunct to specific osteoporosis treatment of patients who are at risk of vitamin D and calcium deficiency.	RED-RED. Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i>
Colesevelam 625mg capsules (<i>Cholestagel</i>) (Genzyme)	Adjunct to diet in primary hypercholesterolaemia either with a statin for patients inadequately controlled on statin alone or as monotherapy when a statin is inappropriate or not tolerated. Adjunct to ezetimibe with or without a statin in primary hypercholesterolaemia.	RED-RED. Not approved for inclusion in the <i>Lincolnshire Joint Formulary</i>
Colesevelam 625mg capsules (<i>Cholestagel</i>) (Genzyme)	For the treatment of chronic diarrhoea or intractable pruritis in patients with bile acid malabsorption, second line after cholestyramine. For the treatment of diarrhoea caused by lenalidomide	AMBER without shared care. Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> for this indication. Should be used second line after cholestyramine. AMBER without shared care. Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> for this indication. Should be used second line after cholestyramine.
Infliximab intravenous infusion (<i>Remicade/Inflectra/Remsima</i>)	For the treatment of moderately to severely active ulcerative colitis in adults. For the treatment of severely active ulcerative colitis in children and young people aged 6 to 17. Lower cost biosimilar infliximab.	RED Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> for these indications.
Meningococcal group B vaccine (<i>Bexsero</i>) (Novartis Vaccines)	For active immunisation against invasive disease cause by <i>Neisseria meningitidis</i> group B.	RED-RED. Should only be prescribed on the NHS for the management of outbreaks of invasive meningococcal disease where the vaccine may be prescribed for close contacts of cases following a request from a Public Health England consultant or nurse. May also be indicated in the same high risk groups that are currently offered ACWY conjugate vaccine.

Methylphenidate hydrochloride 18mg and 36mg sustained release tablets (<i>Xenidate XL</i>) (Mylan)	For attention deficit hyperactivity disorder (ADHD) in children aged 6 and over. Continuing treatment into adulthood may be appropriate if symptoms persist and there has been clear benefit from treatment in adolescence.	AMBER with shared care. Approved for inclusion in the <i>Lincolnshire Joint Formulary</i> .
<i>Sunsense Ultra SPF 50+</i> lotion (Crawford)	For protection from UV radiation in abnormal cutaneous photosensitivity resulting from genetic disorders or photo-dermatoses, including vitiligo and those resulting from radiotherapy. For chronic or recurrent herpes simplex labialis.	GREEN Subject to ACBS restricted indications (Drug Tariff Part XV Borderline Substances). Included in the <i>Lincolnshire Joint Formulary</i> for these restricted indications. Sunscreens should not be prescribed for any other indication.
<i>theiCal-D3</i> chewable tablets (calcium 1g/vit D3 880i.u.) (Stirling Anglian)	For the prevention and treatment of vitamin D and calcium deficiency in the elderly and as an adjunct to specific osteoporosis treatment of patients who are at risk of vitamin D and calcium deficiency.	GREEN Included in the <i>Lincolnshire Joint Formulary</i> . Preferred chewable once daily preparation.
Tolterodine tartrate 2mg and 4mg sustained release capsules (<i>Neditol XL</i>) (Aspire)	For the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.	GREEN Included in the <i>Lincolnshire Joint Formulary</i> .
<i>Uvistat Lipscreen</i> SPF 50 lip protector (Boston Healthcare) <i>Uvistat Suncream</i> SPF 30 sun cream (Boston Healthcare) <i>Uvistat Suncream</i> SPF 50 sun cream (Boston Healthcare)	For protection from UV radiation in abnormal cutaneous photosensitivity resulting from genetic disorders or photo-dermatoses, including vitiligo and those resulting from radiotherapy. For chronic or recurrent herpes simplex labialis.	GREEN Subject to ACBS restricted indications (Drug Tariff Part XV Borderline Substances). Included in the <i>Lincolnshire Joint Formulary</i> for these restricted indications. Sunscreens should not be prescribed for any other indication.

RED-RED: This signifies that a product is **not recommended** for prescribing in **either** primary or secondary care. All new products are classified as RED-RED pending assessment by PACEF.

RED: This signifies that a product has been approved for use within secondary care, tertiary care or a primary care hosted specialist service only and **should not be routinely prescribed in primary care**. RED drugs may be used within ULHT or LPFT subject to approval for use within each Trust. ULHT and LPFT reserve the right to determine whether or not RED drugs will be used within their Trusts. RED classification does not automatically signify that a drug will be available within secondary/tertiary care.

AMBER: This signifies that a drug has been approved for use in primary care **subject to specialist initiation; a shared care guideline (SCG) may also be required**. The main purpose of the SCG will be to clearly define both specialist and GP responsibilities. Not all AMBER drugs that require SCGs are currently covered by formal documents; PACEF are working to rectify this.

GREEN: This signifies a product that is **approved for initiation in either primary or secondary care**.

This bulletin has been created specifically to convey details of decisions taken at the Prescribing and Clinical Effectiveness Forum (PACEF) to all stakeholders across the Lincolnshire Healthcare Community in both primary and secondary care. Back issues of the *PACE Bulletin* and *PACE Shorts* are available through the PACEF website (<http://lincolnshire-pacef.nhs.uk>); follow the commissioning link to PACEF. Electronic copies of the *PACE Bulletin* are circulated to a wide readership via email. If you are not currently on our distribution list and wish to receive regular copies of PACEF publications please contact Sandra France on sandra.france@gemcsu.nhs.uk.

Google searching can be a quick and effective way of finding back numbers of the *PACE Bulletin* relevant to a specific topic of interest. Searchers are advised to use the official version of the *Bulletin* available from the PACEF website rather than depend on a potentially unreliable draft or variant found through Google or an alternative search engine.

The *Lincolnshire Joint Formulary* is available on line and is fully searchable; it can be accessed at www.lincolnshirejointformulary.nhs.uk

THIS DOCUMENT IS INTENDED FOR USE BY NHS HEALTHCARE PROFESSIONALS ONLY AND CANNOT BE USED FOR COMMERCIAL OR MARKETING PURPOSES WITHOUT PERMISSION